New study by Professor Yoon-Kyoung Cho validates urine-based biomarkers for early detection of cancer.
A team of researchers, led by Professor Yoon-Kyoung Cho of Life Science at UNIST has recently developed a new technique that effectively identifies cancer-causing substances in the urine or blood.
In the study, Professor Yoon-Kyoung Cho of Life Science, a group leader at IBS Research Center for Soft and Living Matter (CSLM) presented an integrated centrifugal microfluidic
platform (Exodisc), a device that isolates extracellular vesicles (EVs) from urine.
The results of the study has been published in the February issue of ACS Nano journal. The research team expects that this may be potentially useful in clinical settings to test urinary EV-based biomarkers for cancer diagnostics.
Despite the increasing clinical importance of EVs as potential biomarkers in the diagnosis and prognosis of various diseases, current methods of EV isolation and analysis suffer from complicated procedures with long processing times. For instance, even ultracentrifugation (UC), the most commonly used method for EV isolation, requires time-consuming steps involving centrifugation and acquisition of large sample volumes, and the results suffer from low yield and purity.
To overcome these limitations, Professor Cho presented a new lab-on-a-disc platform for rapid, size-selective, and efficient isolation and analysis of nanoscale EVs from raw biological samples, such as cell-culture supernatant (CCS) or cancer-patient urine.
“The Exodisc is compoased of two independent filteration units (20nm and 600nm in size) within a disk-shaped chip to enable the processing of two different samples simulateously,” says Hyun-Kyung Woo (Combined M.S./Ph.D. student of Natural Science), the first author of the study. “Upon spinning the disc, the urine sample is transferred through two integrated nanofilters, allowing for the enrichment of unirary EVs within the size range of 20 to 600 nm.”
The hole sizes in nanoporous filters mounted on the Exodisc were set arbitrarily to seperate the nanoscale vesicles effectively from germs or unnecessary proteins. The direct detection of urinary EVs from patients with bladder cancer was validated successfully, using on-disc enzyme-linked immunosorbent assay (ELISA).
“Using Exodisc, it is possible to isolate EVs from raw samples within 30 minutes,” says Professor Cho. “The process of passing the filter through centrifugal force is automatically carried out, effectively recovering the enriched EVs.”
In the study, the research team examined clinical samples by analyzing urinary EVs from bladder cancer patients, using a tabletop-sized centrifugal microfluidic system. As a result, fully automated enrichment of unirary EVs in the size range of 20?600 nm was achieved within 30 min Quantitative tests.
“On-disc ELISA using urinary EVs isolated from bladder cancer patients showed high levels of CD9 and CD81 expression, suggesting that this method may be potentially useful in clinical settings to test urinary EV-based biomarkers for cancer diagnostics,” says Vijaya Sunkara of Life Sciences, the co-first author.
“We are currently conducting further studies to determine various diseases, including cancer by analyzing the collected nanoparticles,” says Professor Cho. “We hope this device can contribute significantly to the advancement of studies related to tumor biology and acceleration of the practical use of EV-based liquid biopsies for personalized medicine in clinical settings,” says Professor Cho.
Receive an email update when we add a new CANCER DIAGNOSTICS article.
The Latest on: Cancer diagnostics
via Google News
The Latest on: Cancer diagnostics
- Molecular Diagnostics is Up, Other Test Volume is Down, Kalorama Survey Findson May 12, 2020 at 3:00 am
A survey of clinical labs across the U.S. shows a troubling reduction in testing volume due to the COVID-19 pandemic, with cancer and ...
- Impact Assessment of COVID-19 on the Worldwide Exosome Diagnostics and Treatment Industry (2019 to 2027)on May 12, 2020 at 2:29 am
The "Exosome Diagnostics and Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product; ...
- FDA OKs Myriad test as companion diagnostic for Lynparza in ovarian canceron May 11, 2020 at 9:21 am
The FDA approves Myriad Genetics' (MYGN +6.6%) myChoice CDx test for use as a companion diagnostic to identify suitable patients for AstraZeneca (AZN +0.8%) and Merck's (MRK +1.3%) Lynparza (olaparib) ...
- Decline in cancer diagnoses due to corona crisison May 11, 2020 at 8:12 am
Cancer care has dramatically changed as a result of the measures taken during the COVID-19 pandemic: Many patients have not been going to their GPs, or putting it off, and have been referred to the ...
- Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Canceron May 11, 2020 at 6:48 am
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx® test for use as a co ...
- Impact Of COVID-19 On Kidney Cancer Therapeutics and Diagnostics Market Analysis By Growth, Emerging Trends and Future Opportunities Till 2025on May 11, 2020 at 5:39 am
Kenneth Research has published a detailed report on Kidney Cancer Therapeutics and Diagnostics Market which has ...
- Kristen Biel lost her job after cancer diagnosis. The Supreme Court will decide if she's barred from suing.on May 11, 2020 at 5:38 am
Courts have long acknowledged an exception in the law that keeps "ministers" of a faith from bringing employment discrimination claims against their religious employers, capped by a unanimous Supreme ...
- Reducing Risk Of Fatal Breast Cancer, Study Confirms Strategyon May 11, 2020 at 5:12 am
Researchers analyzed more than a half million women in Sweden and found early mammogram screening significantly reduces the rates of advanced and fatal breast cancer. Their findings are published ...
- How Cancer Shaped a Nurse's Approach To Patient Careon May 10, 2020 at 7:03 am
A few years ago, Wilson said she had a patient who was scared about having a line placed in her chest. This needed to be done for infusion of pulmonary hypertension treatment. The patient was ...
via Bing News